Skip to main content

Aurinia Pharmaceuticals Inc. (AUPH) Stock Forecast

Data as of Oct 31, 2026

Healthcare · Current price $16.69 (-3.08%)

Consensus Target
$16.00
Upside
-4.1%
Analysts
2
Rating
Buy(2.50)

Price Target Range

Low $16.00High $16.00

Consensus Price Target Over Time

Analyst Rating Distribution

Last 3 Months

Consensus
Buy
Strong Buy0
Buy1
Hold1
Sell0
Strong Sell0

6-Month Trend

Latest Analyst Forecasts

Price targets issued by Wall Street analysts. Upside calculated against today's price.

DateAnalystFirmPrice TargetUpside
Sep 6, 2024Ed ArceH.C. Wainwright$13.00-22.1%
May 2, 2024Maury RaycroftJefferies$6.00-64.1%

AUPH vs Sector & Market

MetricAUPHHealthcare AvgLarge Cap Avg
Analyst Rating2.502.252.41
Analyst Count2819
Target Upside-4.1%+153002.0%+21.5%
P/E Ratio8.063.4638.49

Revenue Estimates

PeriodLowAvgHigh#
2026-12-31$83M$86M$90M2
2027-12-31$366M$384M$413M5
2028-12-31$426M$443M$485M5
2029-12-31$448M$466M$510M2
2030-12-31$497M$517M$565M2

EPS Estimates

PeriodLowAvgHigh#
2026-12-31$0.20$0.21$0.221
2027-12-31$0.67$1.06$1.464
2028-12-31$0.43$1.27$2.124
2029-12-31$1.19$1.26$1.412
2030-12-31$1.56$1.64$1.842

Frequently Asked Questions

What is the analyst consensus for AUPH?

The consensus among 2 analysts covering Aurinia Pharmaceuticals Inc. (AUPH) is Buy with an average price target of $16.00.

What is the highest price target for AUPH?

The highest price target for AUPH is $13.00, set by Ed Arce at H.C. Wainwright on 2024-09-06.

What is the lowest price target for AUPH?

The lowest price target for AUPH is $6.00, set by Maury Raycroft at Jefferies on 2024-05-02.

How many analysts cover AUPH?

2 analysts have issued ratings for Aurinia Pharmaceuticals Inc. in the past 12 months.

Is AUPH a buy or sell right now?

Based on 2 analyst ratings, AUPH has a consensus rating of Buy (2.50/5) with a -4.1% upside to the consensus target of $16.00.

What are the earnings estimates for AUPH?

Analysts estimate AUPH will report EPS of $0.21 for the period ending 2026-12-31, with revenue estimated at $86M.

Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.